Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose safety, tolerability, reactogenicity, and pharmacokinetic study of bapineuzumab (AAB 001) administered subcutaneously in subjects with mild to moderate AD.

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose safety, tolerability, reactogenicity, and pharmacokinetic study of bapineuzumab (AAB 001) administered subcutaneously in subjects with mild to moderate AD.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2013

At a glance

  • Drugs Bapineuzumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Apr 2010 Planned end date changed from 1 Mar 2010 to 1 Jun 2010 as reported by ClinicalTrials.gov.
    • 28 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top